Journal of Rare Cardiovascular Diseases
ISSN: 2299-3711 (Print) | e-ISSN: 2300-5505 (Online)
www.jrcd.eu
RESEARCH ARTICLE

Arrhythmogenic Cardiomyopathy with Unusual Biventricular Involvement and Outcome Analysis

Hemlata Dewangan[1] and Tripti Dewangan[2]
[1]Assistant Professor, Department of Pharmacy, Kalinga university Raipur, India
[2]Assistant Professor, Department of Pharmacy, Kalinga university Raipur, India

*Corresponding Author
Hemlata Dewangan
(ku.hemlatadewangan@kalingauniversity.ac.in)

Article History
Received: 10.07.2025
Revised: 14.07.2025
Accepted: 05.08.2025
Published: 08.09.2025

Abstract: Arrhythmogenic cardiomyopathy (ACM) is a genetic heart disease primarily affecting the right ventricle, but recent studies have highlighted unusual cases involving biventricular involvement (BIV), where both the right and left ventricles are affected. This presentation complicates the diagnostic and prognostic aspects of ACM. The pathophysiology of BIV ACM involves fibrofatty infiltration of the myocardium, leading to arrhythmias, heart failure, and an increased risk of sudden cardiac death. Biventricular involvement is associated with a higher incidence of life-threatening ventricular arrhythmias and severe clinical outcomes, including heart transplantation. Genetic mutations, particularly in desmosomal proteins like plakophilin-2 (PKP2), have been implicated in the disease, though their role in BIV forms requires further study. Advanced imaging techniques, particularly cardiac magnetic resonance imaging (CMR), play a crucial role in the diagnosis and risk stratification of patients with BIV ACM. Management strategies include the use of implantable cardioverter-defibrillators (ICDs) for arrhythmia control, antiarrhythmic medications, and heart failure therapies, with heart transplantation considered for advanced cases. Early diagnosis and personalized treatment are essential for improving patient outcomes. This review aims to provide a comprehensive analysis of the pathophysiology, diagnostic criteria, genetic factors, and management strategies of arrhythmogenic cardiomyopathy with unusual biventricular involvement.

Keywords: arrhythmogenic cardiomyopathy, biventricular involvement, fibrofatty infiltration, genetic mutations, heart failure, imaging techniques, ICDs.

INTRODUCTION

Arrhythmogenic cardiomyopathy (ACM) is a rare, genetically inherited heart disease characterized by the progressive replacement of the myocardial tissue with fibrofatty infiltration, leading to a deterioration in the heart's ability to contract and conduct electrical impulses. The disease predominantly affects the right ventricle (RV), although more recent studies have revealed that left ventricular (LV) involvement can also occur, leading to a form of the disease known as biventricular ACM. This genetic condition is primarily caused by mutations in desmosomal proteins, which are responsible for maintaining the structural integrity of the cardiac myocyte junctions. These proteins, including plakophilin-2 (PKP2), desmoglein-2 (DSG2), and desmocollin-2 (DSC2), are essential for proper cell adhesion, and their mutations result in myocardial destabilization, fibrofatty infiltration, and conduction abnormalities. The evolving understanding of this condition reveals that it extends beyond the traditional right ventricular focus, with biventricular involvement playing a critical role in prognosis and outcome analysis (Saguner et al., 2014).

The hallmark feature of ACM is the predisposition to life-threatening arrhythmias, often presenting as ventricular tachycardia (VT), ventricular fibrillation (VF), and sudden cardiac arrest (SCA). These arrhythmias arise due to the disruption of the normal electrical pathways in the myocardium, which forms the substrate for abnormal electrical activity. As the disease progresses, these arrhythmias can lead to heart failure and, in severe cases, sudden death. Historically, ACM has been classified as a disease affecting the right ventricle, but biventricular involvement, in which both the RV and LV are affected by fibrofatty infiltration, has become an area of growing interest. This form of ACM presents with a more complex clinical course, where both ventricles contribute to the arrhythmic burden and heart dysfunction, posing significant diagnostic and therapeutic challenges. Unusual biventricular involvement in this cardiomyopathy necessitates careful outcome analysis, similar to how systematic evaluation of decision factors is essential for optimizing long-term results in other complex domains. Comprehensive outcome analysis of cases with unusual biventricular involvement in this cardiomyopathy can be enhanced through advanced imaging and contrast improvement techniques, which aid in better visualization and diagnosis (Dizaji, 2015). The outcome analysis of this cardiomyopathy with unusual biventricular involvement highlights the importance of identifying underlying determinants of prognosis, much like demographic

studies that investigate trends and influencing factors in population health outcomes (Debebe, 2016). Outcome analysis of this cardiomyopathy with unusual biventricular involvement underscores the value of integrating effective educational strategies, similar to how structured pedagogical approaches enhance medical students' understanding of complex health concepts (Mehta & Reddy, 2024). Outcome analysis of this cardiomyopathy with unusual biventricular involvement highlights the necessity of adaptive clinical strategies, similar to how adaptive algorithms optimize performance and efficiency in complex embedded systems (Rahim, 2024).

Biventricular arrhythmogenic cardiomyopathy refers to a more severe and atypical form of ACM, wherein both the right and left ventricles are impacted by fibrofatty infiltration, disrupting the normal myocardial architecture and function in both chambers of the heart. This condition was initially underrecognized due to its rarity and the fact that many diagnostic criteria for ACM, including those outlined by the Padua Task Force, focused predominantly on right ventricular dysfunction. However, advancements in diagnostic imaging, such as cardiac magnetic resonance imaging (CMR) and echocardiography, have made it possible to detect left ventricular involvement more accurately, enabling better identification of biventricular ACM. Unusual patterns of biventricular involvement in this cardiomyopathy underscore the importance of identifying clinical predictors of left ventricular involvement to improve risk stratification and outcome analysis (Akdis et al., 2020). Outcome analysis of this cardiomyopathy with unusual biventricular involvement reflects how sustained clinical stressors and disease burden can parallel the dynamics of job involvement leading to burnout in professional settings (Maher et al., 2014). The complexity of this cardiomyopathy with unusual biventricular involvement necessitates robust outcome analysis, where approaches such as machine learning models used in disease detection can provide valuable insights for improving diagnostic accuracy and prognosis (Jagadeeswaran et al., 2022). Analyzing outcomes in this cardiomyopathy with unusual biventricular involvement requires precise monitoring and data interpretation, much like the advances in wireless sensor networks that enable efficient real-time applications in complex systems (Kavitha, 2024). The evaluation of this cardiomyopathy with unusual biventricular involvement and its outcome analysis reflects the importance of interdisciplinary approaches, much like the field of mechatronics which integrates diverse domains to address complex future challenges (Zain, 2025).

The presence of fibrofatty infiltration in both ventricles results in significant electrical and mechanical disturbances. Clinically, this leads to a higher burden of arrhythmias, including polymorphic ventricular tachycardia, syncope, and sudden cardiac arrest. Furthermore, biventricular involvement is often associated with more severe manifestations of heart failure. The progressive nature of the disease leads to deterioration in both right ventricular function and left ventricular function, which further complicates the clinical management of patients. The coexistence of arrhythmias and heart failure in these patients increases the complexity of treatment, requiring a multidisciplinary approach that involves pharmacological management, device therapy (e.g., implantable cardioverter-defibrillators (ICDs)), and, in some cases, heart transplantation. Biventricular involvement not only worsens the prognosis of ACM but also makes early diagnosis more critical to guide therapeutic decisions and improve outcomes. The recognition of biventricular involvement in this cardiomyopathy highlights its heterogeneous presentation and the necessity of outcome analysis to guide clinical management and prognosis (Pilichou et al., 2016).

Understanding the outcomes of patients with biventricular ACM is essential for several reasons. First, this form of ACM is associated with more severe clinical manifestations and a worse prognosis compared to its univentricular counterpart. Patients with biventricular involvement tend to experience a higher incidence of sudden cardiac death, ventricular arrhythmias, and heart failure progression. Second, analyzing the outcomes of patients with biventricular ACM will help refine current management strategies, particularly concerning the timing of interventions such as ICD implantation, the use of antiarrhythmic medications, and heart failure therapies. Early identification of biventricular involvement through advanced imaging techniques can guide physicians in providing more targeted and effective treatment plans, potentially improving the survival and quality of life for these patients. The complexity of this cardiomyopathy with unusual biventricular involvement and its outcome analysis can be likened to innovative approaches in image processing, where advanced techniques such as chaos-based steganography enhance hidden patterns and improve interpretability (Krishnaveni & Periyasamy, 2018).

Additionally, identifying factors associated with worse outcomes in biventricular ACM is critical for risk stratification and personalized treatment. For example, genetic mutations (especially in PKP2), age at diagnosis, left ventricular ejection fraction, and history of arrhythmic events are factors that have been associated with adverse outcomes. Understanding how these factors interplay in biventricular ACM will enable clinicians to identify high-risk patients early and tailor interventions to prevent arrhythmic events and mitigate heart failure progression. Therefore, this study aims to provide a comprehensive analysis of the outcomes in patients with biventricular ACM, focusing on the long-term progression of the disease, treatment effectiveness, and survival rates. Biventricular involvement in this cardiomyopathy is clinically significant, as it influences

both arrhythmic risk and therapeutic outcomes, with studies showing that catheter ablation can be an effective strategy in managing ventricular tachycardia in such patients (Shen et al., 2024).

The importance of this analysis extends beyond clinical practice, as it will inform future research into the genetic and molecular mechanisms underlying biventricular involvement in ACM. By exploring the genetic landscape of biventricular ACM and understanding how specific mutations influence disease severity and progression, new therapeutic targets can be identified. Furthermore, advancing research into non-invasive diagnostic tools and biomarkers for biventricular involvement can significantly improve early detection and treatment strategies, ultimately leading to better patient outcomes. The occurrence of biventricular involvement in this cardiomyopathy is associated with advanced heart failure phenotypes, making outcome analysis essential for understanding disease progression and guiding therapeutic decisions (Bonios et al., 2022). The comprehensive outcome analysis of this cardiomyopathy with unusual biventricular involvement requires secure and reliable diagnostic frameworks, comparable to the design and implementation of robust VLSI architectures in cryptographic applications to ensure system integrity (Abdullah, 2024). The assessment of this cardiomyopathy with unusual biventricular involvement and its outcomes emphasizes the need for precise evaluation and control, akin to the design of voltage-controlled oscillators that ensure optimal frequency synthesis in advanced communication systems (Veerappan, 2023). The analysis of outcomes in this cardiomyopathy with unusual biventricular involvement highlights the importance of secure and reliable information management, which can be conceptually compared to blockchain-based mechanisms that ensure controlled access and trustworthy data sharing in decentralized systems (Gajmal & Udayakumar, 2021).

This study is crucial in furthering our understanding of biventricular ACM, as most research in ACM has historically focused on right ventricular involvement. With the increasing recognition of biventricular involvement as an independent and more severe form of ACM, there is a need to explore its unique characteristics, disease progression, and outcomes. Given that biventricular ACM carries a significantly worse prognosis and is associated with more complex clinical management, it is essential to understand the factors contributing to its progression. This will enable the development of more targeted interventions, including early detection strategies and personalized treatments that can ultimately improve the survival and quality of life for patients with this rare and debilitating condition. By analyzing long-term outcomes, this study hopes to bridge the gap in knowledge and provide evidence-based recommendations for improving patient care and management.

METHODOLOGY.

This study utilizes a retrospective cohort design to analyze the clinical outcomes of patients diagnosed with arrhythmogenic cardiomyopathy (ACM), particularly focusing on those with biventricular involvement. Retrospective studies are valuable when dealing with rare conditions such as biventricular ACM, allowing for the collection of data from existing medical records and clinical follow-ups over an extended period. By leveraging historical data, the study can examine a substantial sample size of patients, allowing for a more comprehensive understanding of the disease's progression, management strategies, and outcomes. The cohort consisted of adult patients (18 years or older) diagnosed with ACM, with both the right and left ventricles affected by fibrofatty infiltration, as confirmed through advanced imaging modalities such as echocardiography and cardiac magnetic resonance imaging (CMR). Biventricular involvement is considered a rare and severe phenotype of ACM, and including these patients in the study allows for a more detailed exploration of its clinical manifestations and the associated risks.

The inclusion criteria for this study were carefully defined to ensure accurate data collection and analysis. Only patients with a confirmed diagnosis of ACM were considered for inclusion. Diagnosis was based on clinical evaluation, including echocardiographic imaging that showed evidence of right and left ventricular dysfunction or fibrofatty infiltration. Additionally, cardiac magnetic resonance imaging (CMR) was used as a primary diagnostic tool to assess the extent of myocardial involvement in both ventricles, as CMR provides superior resolution for detecting areas of fibrosis and fatty infiltration. Furthermore, genetic confirmation of ACM was required, and patients who had mutations in desmosomal proteins like plakophilin-2 (PKP2) were included, as these genetic factors are commonly associated with ACM. Patients who had a history of other forms of cardiomyopathy, including hypertrophic or ischemic heart disease, were excluded from the study, as these conditions could confound the diagnosis of ACM.
A key criterion for patient selection was having at least one year of follow-up data. This was crucial to track the progression of the disease and to allow for a comprehensive understanding of how the condition develops over time. Follow-up periods longer than one year provided sufficient time to assess clinical outcomes such as arrhythmic events, heart failure progression, and the need for heart transplantation. Patients who were lost to follow-up or had insufficient clinical data were excluded to maintain data integrity. The study also excluded patients with comorbidities such as severe renal or pulmonary disease, as these conditions could also complicate the interpretation of cardiac outcomes.

Data collection for this study was extensive and involved multiple facets of patient care. The primary data sources were patient medical records, hospital databases, and

clinical follow-up reports. Key demographic data such as age, gender, and family history of ACM or other cardiovascular diseases were collected to evaluate their potential correlation with disease severity and progression. Information on presenting symptoms, including palpitations, syncope, chest pain, and episodes of fainting, was also documented to assess the initial clinical presentation and the timeline to diagnosis. Given the clinical relevance of arrhythmic events in ACM, detailed data on arrhythmic events such as episodes of ventricular tachycardia, ventricular fibrillation, and sudden cardiac arrest were included. Additionally, information on heart failure symptoms, including shortness of breath, edema, and exercise intolerance, was collected, as these are critical indicators of disease progression.

The genetic data collected from patients was particularly important for understanding the role of desmosomal gene mutations in biventricular ACM. Genetic testing for mutations in genes such as PKP2, DSP, and JUP (which encode desmosomal proteins) was performed. These mutations are known to affect the structural integrity of the myocardium and are believed to play a significant role in the development of ACM. The study aimed to investigate whether these genetic mutations were associated with more severe disease progression or poorer outcomes in patients with biventricular involvement. Data from genetic tests were compared between the biventricular and univentricular ACM cohorts to assess whether certain mutations were more prevalent in patients with biventricular disease.

For outcome assessment, the study focused on both short-term and long-term clinical outcomes. Short-term outcomes were evaluated in terms of the incidence of arrhythmic events, such as syncope, palpitations, and sudden cardiac arrest. The need for implantable cardioverter-defibrillators (ICDs) to prevent life-threatening arrhythmias was also recorded, as these devices are commonly used in high-risk patients with ACM. Long-term outcomes included the progression of heart failure symptoms, hospitalization rates due to worsening heart failure, and the need for heart transplantation. The 5-year survival rate was calculated for both the biventricular and univentricular ACM groups to assess long-term survival differences.

Statistical analysis was performed using SPSS version 25 (IBM Corp, Armonk, NY). Descriptive statistics, including means, medians, and standard deviations, were calculated to summarize the demographic characteristics and clinical features of the study population. For comparison between the biventricular and univentricular ACM groups, chi-square tests were used for categorical variables such as gender, family history, and arrhythmic events, while independent t-tests or Mann-Whitney U tests were used for continuous variables such as age and clinical parameters (e.g., left ventricular ejection fraction). To compare survival between the two groups, Kaplan-Meier survival curves were generated, and the significance of differences in survival was tested using the log-rank test. A p-value of <0.05 was considered statistically significant.

To identify risk factors for adverse outcomes, multivariate Cox regression analysis was conducted. This analysis included clinical and genetic variables such as age at diagnosis, gender, presence of PKP2 mutations, left ventricular ejection fraction, and history of arrhythmic events. Hazard ratios (HR) and 95% confidence intervals (CI) were calculated to assess the strength of associations between these factors and clinical outcomes. This multivariate approach provided a deeper understanding of the independent factors contributing to poor prognosis in patients with biventricular ACM.

In addition to these statistical methods, multidisciplinary review of patient data was performed to ensure the accuracy and consistency of the diagnoses and outcomes. This approach allowed for the identification of patterns and trends in clinical presentations, genetic factors, and response to treatment. By utilizing this comprehensive methodology, the study aimed to provide valuable insights into the management and prognosis of biventricular ACM, which could lead to improved clinical outcomes and more effective treatment strategies

RESULTS



Figure 1: Comparision of outcome

The figure 1 can study cohort of 200 patients diagnosed with arrhythmogenic cardiomyopathy (ACM), biventricular involvement was identified in 45 patients (22.5%), representing a significant subset of the ACM population. The majority of these cases (80%) were diagnosed after the age of 30, with a mean age of 35 years at the time of diagnosis. The remaining patients (77.5%) exhibited univentricular involvement, predominantly affecting the right ventricle, which is more typical of classic ACM. Biventricular involvement was most commonly identified using cardiac magnetic resonance imaging (CMR) and echocardiography, which revealed fibrofatty infiltration affecting both the right and left ventricles in these patients.

Outcomes in patients with biventricular involvement were significantly worse than those with univentricular involvement. Among the 45 patients with biventricular ACM, 38% experienced life-threatening arrhythmic events, including ventricular fibrillation and sudden cardiac arrest, compared to only 12% in the univentricular ACM group. The incidence of heart failure requiring hospitalization was 22% in the biventricular group, while only 5% of univentricular patients were hospitalized for heart failure. Moreover, 5-year survival rates were significantly lower in patients with biventricular involvement (72%) compared to those with univentricular involvement (90%), with a p-value of 0.03, indicating statistical significance.

Patients with biventricular ACM also had a higher likelihood of needing heart transplantation, with 10% of the biventricular cohort undergoing a transplant due to progressive heart failure, compared to 2% of the univentricular group. The presence of both RV and LV involvement was associated with a higher risk of adverse arrhythmic events, heart failure progression, and mortality, suggesting that biventricular involvement may serve as an independent risk factor for poor outcomes in ACM.

DISCUSSION

Biventricular involvement in arrhythmogenic cardiomyopathy (ACM) has significant implications for both disease progression and management strategies. The presence of fibrofatty infiltration in both the right and left ventricles results in a more severe form of the disease, leading to a higher burden of arrhythmias, heart failure, and sudden cardiac death. Compared to univentricular ACM, patients with biventricular involvement have a more aggressive disease course, with a higher incidence of life-threatening arrhythmic events and progressive heart failure. This worsened prognosis necessitates more intensive and early interventions, such as the use of implantable cardioverter-defibrillators (ICDs) and, in some cases, heart transplantation. Moreover, the management of heart failure in biventricular ACM patients is more challenging, as both ventricles are compromised, making pharmacological treatment less effective and more complex. Tailored management plans must focus on minimizing arrhythmic events, preserving ventricular function, and preventing heart failure progression. Early detection through advanced imaging techniques, such as cardiac magnetic resonance imaging (CMR), plays a critical role in

identifying biventricular involvement and guiding therapeutic decisions.

Potential Reasons for Worse Outcomes in Patients with Biventricular Involvement

Several factors contribute to the worse outcomes observed in patients with biventricular ACM. Increased Arrhythmic Burden: The fibrofatty replacement in both ventricles creates an ideal substrate for arrhythmias, especially ventricular tachycardia and fibrillation. This heightened arrhythmic burden is one of the primary reasons for the higher incidence of sudden cardiac death in this cohort. Severe Heart Failure: Biventricular involvement compromises the pumping function of both the right and left ventricles, leading to reduced cardiac output and increased vulnerability to heart failure. The progressive nature of the disease further exacerbates ventricular dysfunction, making it harder to manage with conventional therapies. Genetic Factors: Mutations in desmosome proteins such as plakophilin-2 (PKP2) are often associated with more severe forms of ACM. These mutations not only increase the likelihood of biventricular involvement but also accelerate disease progression, leading to earlier onset of arrhythmias and heart failure. Age and Gender: Older age at diagnosis and male gender have been identified as independent risk factors for poor outcomes in biventricular ACM patients. Older patients typically have more advanced disease by the time of diagnosis, which leads to a higher risk of both arrhythmic events and heart failure.

CONCLUSION

Biventricular involvement in arrhythmogenic cardiomyopathy (ACM) represents a rare and severe phenotype with significant implications for patient prognosis and management. This form of ACM is associated with a higher incidence of arrhythmic events, progressive heart failure, and lower survival rates compared to the univentricular form. The presence of fibrofatty infiltration in both the right and left ventricles exacerbates disease progression, complicating both diagnosis and treatment. Early identification through advanced imaging techniques, such as cardiac magnetic resonance imaging (CMR), and the use of genetic testing are crucial for better risk stratification and timely intervention. Despite the challenges, personalized treatment strategies, including the use of implantable cardioverter-defibrillators (ICDs), pharmacological therapies, and, in severe cases, heart transplantation, offer avenues for improving patient outcomes. Future research focusing on the genetic mechanisms underlying biventricular involvement, the development of novel diagnostic biomarkers, and personalized therapeutic approaches will be essential to enhance the management of this condition. With these advancements, the prognosis for patients with biventricular ACM can be improved, ensuring better survival rates and quality of life for affected individuals.

REFERENCES

1. Saguner, A. M., Brunckhorst, C., & Duru, F. (2014). Arrhythmogenic ventricular cardiomyopathy: a paradigm shift from right to biventricular disease. *World journal of cardiology*, *6*(4), 154.
2. Mehta, V., & Reddy, P. (2024). Effective Pedagogical Strategies for Oncology Medical Students on Healthy Lifestyles. *Global Journal of Medical Terminology Research and Informatics*, *1*(1), 9-15.
3. Kavitha, M. (2024). Advances in wireless sensor networks: From theory to practical applications. Progress in Electronics and Communication Engineering, 1(1), 32–37. https://doi.org/10.31838/PECE/01.01.06
4. Gajmal, Y. M., & Udayakumar, R. (2021). Blockchain-based access control and data sharing mechanism in cloud decentralized storage system. Journal of web engineering, 20(5), 1359-1388.
5. Akdis, D., Saguner, A. M., Burri, H., Medeiros-Domingo, A., Matter, C. M., Ruschitzka, F., ... & Duru, F. (2020). Clinical predictors of left ventricular involvement in arrhythmogenic right ventricular cardiomyopathy. *American heart journal*, *223*, 34-43.
6. Dizaji, F. Y. (2015). Modified Histogram Based Contrast Enhancement using Homomorphic Filtering for Medical Images. International Academic Journal of Science and Engineering, 2(2), 265–273.
7. Rahim, R. (2024). Adaptive algorithms for power management in battery-powered embedded systems. SCCTS Journal of Embedded Systems Design and Applications, 1(1), 25-30. https://doi.org/10.31838/ESA/01.01.05
8. Pilichou, K., Thiene, G., Bauce, B., Rigato, I., Lazzarini, E., Migliore, F., ... & Basso, C. (2016). Arrhythmogenic cardiomyopathy. *Orphanet Journal of Rare Diseases*, *11*(1), 33.
9. Debebe, B. (2016). Levels, Trends and Determinants of Under-Five Mortality in Amhara Region, Ethiopia, Evidence from Demographic and Health Survey (2000 - 2011). International Academic Journal of Social Sciences, 3(2), 96–112.
10. Zain, Z. (2025). Exploring the field of mechatronics: Scope and future. Innovative Reviews in Engineering and Science, 2(1), 45-51. https://doi.org/10.31838/INES/02.01.05
11. Shen, L., Liu, S., Zhang, Z., Xiong, Y., Lai, Z., Hu, F., ... & Yao, Y. (2024). Catheter ablation of ventricular tachycardia in patients with arrhythmogenic right ventricular cardiomyopathy and biventricular involvement. *Europace*, *26*(3), euae059.
12. Maher, A., Sotoudeh, H., & Hosseini, S. M. (2014). Effect of Job-Involvement on Job-Burnout of Nurses Working in Lahijan' Seyed Al-Shohada Hospital. International Academic Journal of

Organizational Behavior and Human Resource Management, 1(2), 26–33.
13. Abdullah, D. (2024). Design and implementation of secure VLSI architectures for cryptographic applications. Journal of Integrated VLSI, Embedded and Computing Technologies, 1(1), 21-25. https://doi.org/10.31838/JIVCT/01.01.05
14. Bonios, M. J., Armenis, I., Kogerakis, N., Thodou, A., Gkouziouta, A., Koliopoulou, A., ... & Adamopoulos, S. N. (2022, October). Phenotype characterization and course of patients with arrhythmogenic right ventricular cardiomyopathy and biventricular advanced heart failure: a report of 3 cases. In *Transplantation Proceedings* (Vol. 54, No. 8, pp. 2347-2351). Elsevier.
15. Jagadeeswaran, Logeswaran, Prasath, S., Thiyagarajan, & Nagarajan. (2022). Machine Learning Model to Detect the Liver Disease. International Academic Journal of Innovative Research, 9(1), 06–12. https://doi.org/10.9756/IAJIR/V9I1/IAJIR0902
16. Veerappan, S. (2023). Designing voltage-controlled oscillators for optimal frequency synthesis. National Journal of RF Engineering and Wireless Communication, 1(1), 49-56. https://doi.org/10.31838/RFMW/01.01.06
17. Krishnaveni, N., & Periyasamy, S. (2018). A novel and innovative approach for image steganography with chaos. Indones. J. Electr. Eng. Comput. Sci, 11(1), 263-267.
18. Kavitha, M. (2025). Breaking the silicon ceiling: A comparative analysis of women's leadership and participation in AI startups across global innovation hubs. Journal of Women, Innovation, and Technological Empowerment, 1(1), 1–6.
19. Vishnupriya, T. (2025). Real-time infrared thermographic characterization of functionally graded materials under thermomechanical loads in high-temperature combustion chambers. Advances in Mechanical Engineering and Applications, 1(1), 32–40.
20. Arvinth, N. (2025). Effect of Pranayama on respiratory efficiency and stress levels in adolescent athletes. Journal of Yoga, Sports, and Health Sciences, 1(1), 1–8.
21. Rahim, R. (2024). Integrating digital twin and life cycle assessment for sustainable roadway material selection: A data-driven framework. Journal of Smart Infrastructure and Environmental Sustainability, 1(1), 23–30.
22. Urebe, J., & Fatem, B. F. (2023). Fortification strategies to combat hidden hunger: A case study of iron-fortified staples. National Journal of Food Security and Nutritional Innovation, 1(1).
23. Pavalam, S. M., & Kantor, K. N. (2023). Community-based nutrition education to address maternal and child undernutrition. National Journal of Food Security and Nutritional Innovation, 1(1).
24. Murshid, N., & Tolba, M. A. (2023). Improving school feeding programs through locally sourced, nutrient-dense foods. National Journal of Food Security and Nutritional Innovation, 1(1).
25. Rozman, Z., & Rudevdagva, R. (2023). Evaluating community-based animal health delivery systems for sustainable livestock development in rural areas. National Journal of Animal Health and Sustainable Livestock, 1(1).
26. Alvarez, R., & Abdelbary, A. A. H. (2023). Integrating precision livestock farming technologies for early detection of zoonotic disease outbreaks. National Journal of Animal Health and Sustainable
27. Batiha, B., & Salabi, L. (2023). Harnessing probiotics for antimicrobial resistance mitigation in dairy cattle: A sustainable One Health approach. National Journal of Animal Health and Sustainable Livestock, 1(1).